Welcome to Multibagg AI
Log in to access personalized features
IRIS
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Research powered by GOALZEN CAPITAL SERVICES PRIVATE LIMITED · SEBI Research Analyst INH000013448
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stock
Anupam Rasayan India Limited is an India‑headquartered specialty chemicals company focused on custom synthesis and multi‑step manufacturing of intermediates for life sciences, agrochemicals, performance materials, polymers and electronics, operating multiple automated manufacturing facilities in Gujarat and exporting to a diverse base of domestic and global customers including multinational companies.
Q1 FY27 demonstrated operational momentum with commercial launches of differentiated products, notably ETFA via flow chemistry — marketed as a global first — which highlights Anupam Rasayan India Limited's advanced process capabilities, improved safety, environmental footprint, and potential margin benefits in applications across pharma, agro and semiconductor markets.
Management highlighted a USD300 million LOI with BASQUEVOLT (over ten years) and a cumulative pipeline of signed LOIs and contracts of roughly INR18,000 crores, indicating material multi‑year revenue potential for Anupam Rasayan India Limited as multiple new products are commercialized and scaled from FY27 onward.
Financially, consolidated Q1 FY27 total income was INR667.5–668 crores, up 36% year‑on‑year, with EBITDA of ~INR175 crores and margin of 26%, while PAT was INR51 crores; management reports that major capex is largely complete and FY27 capex is expected to be modest, supporting near‑term cash generation for Anupam Rasayan India Limited.
Strategic acquisitions are reshaping the platform: Jayhawk Fine Chemicals adds a U.S. manufacturing base and semiconductor/high‑purity capabilities, and the proposed Bliss GVS Pharma acquisition would extend Anupam Rasayan India Limited into regulated formulations and CDMO capabilities, together creating a vertically broader portfolio and deeper customer access.
Chemicals & Petrochemicals
Specialty Chemicals
12,556 Cr
Low Risk
55.8
35.0
1.4
3.8
1,415.40
1,053.45
Sales CAGR
Profit CAGR
ROE
ROCE
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
427.20 | 15,496 Cr | 29.18 | 2.60 | 0.23 | 7.04 | 6.41 | 3.99 | ||
5054.00 | 15,496 Cr | 35.37 | 5.82 | 0.22 | 15.65 | 20.00 | 14.61 | ||
3069.15 | 13,285 Cr | 21.30 | 3.36 | 0.81 | 10.62 | 14.23 | 7.62 | ||
3247.35 | 12,685 Cr | 37.09 | 8.98 | 0.31 | 23.19 | 21.43 | 10.79 | ||
1102.85 | 12,556 Cr | 55.81 | 3.80 | 0.14 | 5.10 | 7.68 | 2.81 | ||
1070.00 | 11,092 Cr | 24.74 | 3.51 | 0.79 | 14.03 | 18.72 | 12.49 | ||
12234.00 | 9,699 Cr | 54.62 | 8.79 | 0.06 | 16.09 | 21.42 | 13.50 | ||
| Median: 7 Co. | — | 3069.15 | 12,685 Cr | 35.37 | 3.80 | 0.23 | 14.03 | 18.72 | 10.79 |
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Bearish
6
Neutral
6
Bullish
2
Bearish
37
Neutral
6
Bullish
3
Bearish
31
Neutral
0
Bullish
1
Bearish
6
Neutral
6
Bullish
2
Bearish
6
Neutral
6
Bullish
2
Bearish
31
Neutral
0
Bullish
1
Bearish
31
Neutral
0
Bullish
1
Bearish
31
Neutral
0
Bullish
1
Anupam Rasayan India Ltd (ANURAS) is currently trading at 1,098.80 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Anupam Rasayan India Limited is an India‑headquartered specialty chemicals company focused on custom synthesis and multi‑step manufacturing of intermediates for life sciences, agrochemicals, performance materials, polymers and electronics, operating multiple automated manufacturing facilities in Gujarat and exporting to a diverse base of domestic and global customers including multinational companies. Q1 FY27 demonstrated operational momentum with commercial launches of differentiated products, notably ETFA via flow chemistry — marketed as a global first — which highlights Anupam Rasayan India Limited's advanced process capabilities, improved safety, environmental footprint, and potential margin benefits in applications across pharma, agro and semiconductor markets. Management highlighted a USD300 million LOI with BASQUEVOLT (over ten years) and a cumulative pipeline of signed LOIs and contracts of roughly INR18,000 crores, indicating material multi‑year revenue potential for Anupam Rasayan India Limited as multiple new products are commercialized and scaled from FY27 onward. Financially, consolidated Q1 FY27 total income was INR667.5–668 crores, up 36% year‑on‑year, with EBITDA of ~INR175 crores and margin of 26%, while PAT was INR51 crores; management reports that major capex is largely complete and FY27 capex is expected to be modest, supporting near‑term cash generation for Anupam Rasayan India Limited. Strategic acquisitions are reshaping the platform: Jayhawk Fine Chemicals adds a U.S. manufacturing base and semiconductor/high‑purity capabilities, and the proposed Bliss GVS Pharma acquisition would extend Anupam Rasayan India Limited into regulated formulations and CDMO capabilities, together creating a vertically broader portfolio and deeper customer access.
Over the past 52 weeks, Anupam Rasayan India Ltd has traded between a low of ₹1,053.45 and a high of ₹1,415.40. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Anupam Rasayan India Ltd has a market capitalization of approximately 12,555.93. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Anupam Rasayan India Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 55.81 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 12,555.93 Cr, Anupam Rasayan India Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Anupam Rasayan India Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Anupam Rasayan India Ltd is 55.81. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Anupam Rasayan acquired 1,669 equity shares tendered by public shareholders in the open offer.
The company’s board is scheduled to consider raising up to ₹160 crore through secured, rated, unlisted, redeemable NCDs via private placement.
The company filed its Q1 FY27 unaudited financial results with the BSE on August 15, 2026, for the quarter ended June 30, 2026.
The company filed its Q1 FY27 unaudited financial results with the BSE on August 15, 2026, for the quarter ended June 30, 2026.
